PKC-ing is believing: targeting protein kinase C in heart failure.

Stephen L Belmonte, Burns C Blaxall

Abstract readEditorialComment

In one paragraph

Article in Circulation research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it

0cells of the map it votes in

4citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

Extracellular Histone-Induced Protein Kinase C Alpha Activation and Troponin Phosphorylation Is a Potential Mechanism of Cardiac Contractility Depression in Sepsis.International journal of molecular sciences · 2023
Article
Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection.PLoS pathogens · 2015
Article
Rosuvastatin-attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway.Journal of cellular and molecular medicine · 2012
Article
Long QT2 mutation on the Kv11.1 ion channel inhibits current activity by ablating a protein kinase Cα consensus site.Molecular pharmacology · 2012
Article

4 · The record

Corrections and comments

Comment on
Inhibition of PKCα/β with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury.2011

5 · Who and what money

Authors and funding

2 authors.

Stephen L Belmonte

Burns C Blaxall

Funding

Training in Environment ToxicologyT32ES007026 · NIEHS · UNIVERSITY OF ROCHESTER · PI Alison Elder, Marissa Sobolewski Terry · 1985 to 2026

$20.2M

A Role for Mena in the HeartR01HL089885 · NHLBI · UNIVERSITY OF ROCHESTER · PI BLAXALL, BURNS C · 2008 to 2012

$2.2M

Targeting of B-AR/GBy signaling in the heart with small moleculesR01HL091475 · NHLBI · UNIVERSITY OF ROCHESTER · PI BLAXALL, BURNS C · 2010 to 2013

$1.5M

NHLBI NIH HHS R01 HL089885NHLBI NIH HHS R01 HL091475NHLBI NIH HHS R01-HL091475NHLBI NIH HHS R01-HL89885NIEHS NIH HHS 5T32ES07026-33

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsEnzyme InhibitorsFemaleHeart FailureIndolesMaleimidesMyocardial InfarctionProtein Kinase CProtein Kinase C-alphaProtein Kinase C betaEnzyme InhibitorsIndolesMaleimidesProtein Kinase CProtein Kinase C-alphaProtein Kinase C betaruboxistaurin

Identifiers

PMID22158646

DOI10.1161/CIRCRESAHA.111.259358

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.